JP2022530443A5 - - Google Patents

Info

Publication number
JP2022530443A5
JP2022530443A5 JP2021563172A JP2021563172A JP2022530443A5 JP 2022530443 A5 JP2022530443 A5 JP 2022530443A5 JP 2021563172 A JP2021563172 A JP 2021563172A JP 2021563172 A JP2021563172 A JP 2021563172A JP 2022530443 A5 JP2022530443 A5 JP 2022530443A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
antigen
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021563172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530443A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029664 external-priority patent/WO2020219778A2/en
Publication of JP2022530443A publication Critical patent/JP2022530443A/ja
Publication of JP2022530443A5 publication Critical patent/JP2022530443A5/ja
Withdrawn legal-status Critical Current

Links

JP2021563172A 2019-04-24 2020-04-23 抗ｃｄ１１７抗体薬物複合体およびその使用 Withdrawn JP2022530443A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838286P 2019-04-24 2019-04-24
US62/838,286 2019-04-24
PCT/US2020/029664 WO2020219778A2 (en) 2019-04-24 2020-04-23 Anti-cd117 antibody-drug conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2022530443A JP2022530443A (ja) 2022-06-29
JP2022530443A5 true JP2022530443A5 (enExample) 2022-08-23

Family

ID=72940692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563172A Withdrawn JP2022530443A (ja) 2019-04-24 2020-04-23 抗ｃｄ１１７抗体薬物複合体およびその使用

Country Status (4)

Country Link
US (1) US20220177577A1 (enExample)
EP (1) EP3958899A4 (enExample)
JP (1) JP2022530443A (enExample)
WO (1) WO2020219778A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084057A2 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Regeneron Pharmaceuticals, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
JP2022531141A (ja) * 2019-04-24 2022-07-06 マジェンタ セラピューティクス インコーポレイテッド 遺伝子治療のコンディショニング方法
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322610B1 (en) * 2008-07-16 2016-12-14 Medical and Biological Laboratories Co., Ltd. Anti-human clcp1 antibody and use thereof
NZ630363A (en) * 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
PE20181326A1 (es) * 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
IL263744B2 (en) * 2016-06-17 2023-11-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117 plus cells
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
WO2019084057A2 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
KR20200069364A (ko) * 2017-10-24 2020-06-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
JP2021526525A (ja) * 2018-06-07 2021-10-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Regeneron Pharmaceuticals, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
WO2020092655A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Methods for allogeneic hematopoietic stem cell transplantation

Similar Documents

Publication Publication Date Title
JP7650819B2 (ja) 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用
US20260078148A1 (en) Amatoxin antibody-drug conjugates and uses thereof
JP7709376B2 (ja) Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
JP7669269B2 (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
TWI904109B (zh) 抗ｃｄ４５抗體及其結合物
US20220175944A1 (en) Anti-cd117 antibody-drug conjugates and uses thereof
JP2021500375A5 (enExample)
JP2021504412A (ja) Ｃｄ５＋細胞の枯渇のための組成物および方法
JP2022530443A5 (enExample)
JP2022529726A5 (enExample)
US20220177577A1 (en) Anti-cd117 antibody drug conjugates and uses thereof
US20220226493A1 (en) Anthracycline antibody-drug conjugates and uses thereof
JP2022529726A (ja) Ａｎｔｉ－ｃｄ１１７とその使用
US20200376135A1 (en) Fc silenced antibody drug conjugates (adcs) and uses thereof
JP2025172753A (ja) 自己免疫疾患を治療するための方法および組成物
JP2022529727A5 (enExample)
JP2022529727A (ja) Ａｎｔｉ－ｃｄ１１７ とその使用
JP2021517133A (ja) 抗ｃｄ２５２抗体、コンジュゲート、および使用方法